Medicine and Dentistry
Prostate Cancer
100%
Immunity
73%
Immune Checkpoint Inhibitor
70%
Malignant Neoplasm
70%
Immune-Related Adverse Events
51%
Diseases
48%
Germinoma
31%
Surgery
31%
Colitis
25%
Immunosuppressive Treatment
24%
Systemic Therapy
24%
Oncology
23%
Prostatectomy
22%
Urogenital Tract Cancer
19%
Neoplasm
19%
Clinical Trial
19%
Programmed Death 1 Ligand 1
17%
Patient Selection
17%
Prevalence
17%
Solid Malignant Neoplasm
17%
Cytotoxic T-Cell
15%
Myocarditis
15%
Programmed Death-Ligand 1
15%
Toxicity
15%
Androgen Receptor
15%
Edicotinib
15%
Microscopic Colitis
15%
Paraneoplastic Cerebellar Degeneration
15%
Patient-Reported Outcome
15%
Actin
15%
Neutrophil
15%
Invagination
15%
Focal Neurologic Signs
15%
Aroma
15%
Castration Resistant Prostate Cancer
15%
Immunohistochemistry
15%
Patient Monitoring
15%
Cell Shape
15%
Metastatic Breast Cancer
15%
Heart Muscle Biopsy
15%
Purkinje Cell
15%
Hormone Therapy
15%
Local Therapy
15%
Metastatic Carcinoma
12%
Adverse Event
12%
Circulating Tumor DNA
11%
Androgen Deprivation Therapy
10%
Radiation Therapy
10%
Next Generation Sequencing
10%
Skeletal Muscle
10%
Keyphrases
Prostate Cancer
42%
Immune Checkpoint Therapy
39%
Testicular Germ Cell Tumor
31%
Body Composition
31%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
29%
Tumor Microenvironment
25%
Chemotherapy
25%
Immune Checkpoint Inhibitors
25%
Patient Selection
22%
Prostate Tumor
22%
Immune-related Adverse Events
21%
Overall Survival
21%
Resistance Mechanisms
20%
Programmed Death-ligand 1 (PD-L1)
20%
Solid Tumors
19%
Anti-PD-1
19%
Cancer Patients
18%
Colitis
18%
Extragonadal Germ Cell Tumor
15%
Tumor Prognosis
15%
Endomyocardial Biopsy
15%
Molecular Signature
15%
Localized Prostate Cancer
15%
PD-L1 Inhibitor
15%
Bone Microenvironment
15%
ESR1 mutation
15%
Androgen Signaling
15%
Clinical Laboratory Improvement Amendments
15%
Daratumumab
15%
Nave
15%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
15%
Microscopic Colitis
15%
Anti-CD38
15%
Immune Subsets
15%
Checkpoint Inhibitor Colitis
15%
Immune Checkpoint Inhibitor Myocarditis
15%
Focal Neurologic Signs
15%
Systemic Therapy
15%
Selective Immunosuppressive Therapy
15%
Immune Checkpoint
15%
Metastatic Breast Cancer
15%
Neutrophils
15%
Immune Response
15%
Immunohistochemistry
15%
Androgen Receptor
15%
Soroush
15%
Enzalutamide
15%
Programmed Death ligand-1 Blockade
15%
Colony-stimulating Factor 1 Receptor Inhibitor
15%
Cytoplasmic Antibodies
15%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
68%
Immune Checkpoint Inhibitor
63%
Adverse Event
59%
Malignant Neoplasm
51%
Diseases
48%
Overall Survival
33%
Neoplasm
27%
Colitis
25%
Clinical Trial
20%
Urogenital Tract Cancer
19%
Programmed Death 1 Ligand 1
17%
Immunosuppressive Agent
16%
Tumor Microenvironment
16%
Metastatic Breast Cancer
15%
Microscopic Colitis
15%
Myocarditis
15%
Actin
15%
Toxicity
15%
Chemotherapy
15%
Prevalence
15%
Castration Resistant Prostate Cancer
15%
Schistosomiasis
15%
Androgen Receptor
15%
Enzalutamide
15%
Infection
11%
Solid Malignant Neoplasm
11%
Circulating Tumor DNA
11%
Prostate Tumor
10%
Metastasis
10%
Immunotherapy
9%
Durvalumab
9%
Cohort Study
8%
Androgen
8%
Renal Cell Carcinoma
8%
Transitional Cell Carcinoma
8%
Aromatase Inhibitor
7%
Androgen Receptor Antagonist
7%
Myosin II
7%
Atezolizumab
7%
Prostate Specific Antigen
6%
Tremelimumab
6%
Systemic Treatment
6%
Vedolizumab
5%
Progression Free Survival
5%
Recurrent Disease
5%
Infliximab
5%